Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period

Movement Disorders

Volumn 17, Issue 6, 2002, Pages 1288-1293

  Hsiung, G Y R ^a   Das, S K ^a   Ranawaya, R ^a   Lafontaine, A L ^a   Suchowersky, O ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Blepharospasm; Botulinum toxin A; Dystonia; Hemifacial spasm; Spasmodic torticollis

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; BLEPHAROSPASM; DIPLOPIA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DYSPHAGIA; DYSTONIA; FEMALE; FOLLOW UP; HEMIFACIAL SPASM; HUMAN; INJECTION; JAW; LEG; LONG TERM CARE; MAJOR CLINICAL STUDY; MALAISE; MALE; MOTOR DYSFUNCTION; MUSCLE ATROPHY; MUSCLE WEAKNESS; NECK; PATIENT SATISFACTION; PRIORITY JOURNAL; PTOSIS; RETROSPECTIVE STUDY; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; VISUAL IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXIN TYPE A; BRITISH COLUMBIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; LONG-TERM CARE; MALE; MIDDLE AGED; MOVEMENT DISORDERS; PATIENT SATISFACTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0036869216     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10252     Document Type: Review

References (35)

1. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc 1981;79:734-770.
2. Tsui JK, Eisen A, Stoessl AL, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986;2:245-247.
3. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991;324:1186-1191.
4. Dutton JJ, Buckley E.G. Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. Ophthalmology 1988:95:1529-1534.
5. Gelbe DJ, Lowenstein DH, Aminoff MJ. Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis. Neurology 1989;39:80-84.
6. Ruusuvwara P, Setala K. Long-term treatment of involuntary facial spasms using botulinum toxin. Acta Ophthalmol 1990;68:331-338.
7. Blackie JD, Lees AJ. Botulinum toxin in spasmodic torticollis. J Neurol Neurosurg Psychiatry 1990;53:640-643.
8. Greene P, Kang U, Fahn S, et al. Double blind placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1990;40:1213-1218.
9. Mauiello JA, Aijian J. Natural history of treatment of facial dyskinesias with botulinum toxin: a study of 50 consecutive patients over seven years. Br J Ophthalmol 1991;75:737-739.
10. Lorenz IT, Subramanian SS, Yiannikas C. Treatment of idiopathic spasmodic torticollis with botulinum toxin A: a double blind study on 23 patients. Mov Disord 1991;6:145-150.
11. Taylor JDN, Kraft SP, Kazdan MS, et al. Treatment of blepharospasm and hemifacial spasm with botulinum A toxin: a Canadian multicentre study. Can J Ophthalmol 1991;26:133-138.
12. Powe W, Schelosy L, Kleederfer B, Heinet F, Wagner M, Deuschl G. Treatment of spasmodic torticollis with local injections of botulinum toxin: one-year follow up in 37 patients. J Neurol 1992;239:21-25.
13. Jankovic J, Schwartz KS. Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology 1993;43:834-836.
14. Karp BI. Cole RA, Cohen LG, Grill S, Lou JS, Hallett M. Long-term botulinum toxin treatment of focal hand dystonia. Neurology 1994:44:70-76.
15. Vanden Bergh P, Francart J, Mourin S, et al. Five year experience in the focal movement disorders with low dose Dysport TM botulinum toxin. Muscle Nerve 1995;18:720-729.
16. Ainsworth JR, Kraft SP. Long-term changes in duration of relief with botulinum toxin treatment of essential blepharospasm and hemifacial spasm. Ophthalmology 1995;102:2036-2040.
17. Mauriello JA, Dhillon S, Leone T, et al. Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years. Br J Ophthalmol 1996;80:1073-1076.
18. Mauriello JA, Leone T, Dhillon S, et al. Treatment choices of 119 patients with hemifacial spasm over 11 years. Clin Neurol Neurosurg 1996;98:213-216.
19. Chang LB, Tsai CP, Liao KK, Kao KP, Yuan CL, Yen DJ, Lin KP. Use of botulinum toxin A in treatment of hemifacial spasm and blepharospasm. Chung Hua I Hsueh Tsa Chih (Taipei) 1999;62:1-5.
20. Tan KK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology 1999;53:2102-2107.
21. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. J Neurol 1999;246:265-274.
22. Jitpimolmard S, Tiamkao S, Laopaiboon M. Long term results of botulinum toxin A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases. J Neurol Neurosurg Psychiatry 1998;64:751-757.
23. Lal S. Pathophysiology and pharmacotherapy of spasmodic torticollis: a review. Can J Neurol Sci 1979;6:427-435.
24. Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord 1991;6:119-126.
25. Jankovic J, Orman J. Blepharospasm: demographic and clinical survey of 250 patients. Ann Ophthalmol 1984; 16:371-376.
26. Wang A, Jankovic J. Hemifacial spasm: clinical findings and treatment. Muscle Nerve 1998;21:1740-1747.
27. Tan A. Botulinum toxin for neurological disorders in a movement disorders clinic in Singapore. Singapore Med J 1998;39:403-405.
28. Wilkins R. Hemifacial spasm: a review. Surg Neurol 1991;36:251-277.
29. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994;9:213-217.
30. Borodic G, Johnson E, Goodenough M, et al. Botulinum toxin therapy, immunological resistance, and problems with available materials. Neurology 1996;46:26-30.
31. Erbguth F, Claus D, Jaspert A, et al. Which patients discontinue treatment with botulinum toxin in cervical dystonia? [abstract]. Mov Disord 1995;10:371.
32. Brashear A, Bergan K, Wojcieszek J, et al. Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A. Mov Disord 2000;15:150-153.
33. Tsui JK, Hayward M, Mak EK, Schulzer M. Botulinum toxin type B in the treatment of cervical dystonia: a pilot study. Neurology 1995;45:2109-2110.
34. Chen R, Karp BI, Hallett M. Botulinum toxin type F for treatment of dystonia: long-term experience. Neurology 1998;51:1494-1496.
35. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999;53:1431-1438.